Reuters logo
Vertex cystic fibrosis drug succeeds in combo trial
April 18, 2013 / 8:46 PM / in 5 years

Vertex cystic fibrosis drug succeeds in combo trial

April 18 (Reuters) - Vertex Pharmaceuticals Inc said its experimental drug improved lung function in adults with cystic fibrosis in a mid-stage trial, sending its shares up sharply in after-hours trading.

The company said on Thursday the favorable results were seen in patients who took its experimental drug VX-661 in combination with the company’s already approved treatment for cystic fibrosis, Kalydeco (ivacaftor).

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below